Welcome to our dedicated page for PepGen news (Ticker: PEPG), a resource for investors and traders seeking the latest updates and insights on PepGen stock.
PepGen Inc. develops oligonucleotide therapies for severe neuromuscular and neurological diseases. The company’s Enhanced Delivery Oligonucleotide platform uses cell-penetrating peptides to improve tissue penetration, cellular uptake and nuclear delivery of conjugated oligonucleotide therapeutics.
Recurring PepGen news centers on clinical development of PGN-EDODM1 for myotonic dystrophy type 1, including FREEDOM and FREEDOM2 study updates, safety observations, splicing correction data, regulatory communications and trial geography. Coverage also includes financial results, cash runway commentary, intellectual-property developments such as composition-of-matter patent protection, executive and governance updates, and equity compensation actions under Nasdaq rules.
Summary not available.
Summary not available.
Summary not available.
PepGen Inc. (Nasdaq: PEPG), a biotechnology company focused on oligonucleotide therapies, announced its participation in the 2023 American Academy of Neurology Annual Meeting from April 22-27 in Boston. The company will feature two oral and two poster presentations, highlighting advancements in treatments for Myotonic Dystrophy Type 1 (DM1) and Duchenne Muscular Dystrophy (DMD). Ashling Holland, Ph.D., will present preclinical data for DM1 on April 27, while two presentations on DMD will occur on April 23, showcasing results from a Phase 1 study of PGN-EDO51 and a study design for PGN-EDODM1. PepGen aims to revolutionize the treatment landscape for severe neuromuscular diseases through its Enhanced Delivery Oligonucleotide platform, demonstrating a commitment to addressing these critical health challenges.
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company, announced that its President and CEO, James McArthur, Ph.D., will present at the 22nd Annual Needham Virtual Healthcare Conference on April 20th, 2023, at 8:00 AM EDT. The presentation will be available for live streaming and will also be archived for one year on the company’s website. PepGen focuses on advancing next-generation oligonucleotide therapies aimed at severe neuromuscular and neurological diseases, utilizing its Enhanced Delivery Oligonucleotide (EDO) platform. This platform leverages over a decade of research to enhance the uptake and efficacy of oligonucleotide therapeutics through cell-penetrating peptides.
PepGen Inc. (Nasdaq: PEPG) reported its financial results for Q4 and full year 2022, highlighting significant advancements in its clinical pipeline. The company generated first-in-human data for PGN-EDO51, targeting Duchenne muscular dystrophy (DMD), and plans to initiate Phase 2 studies in 2023. Financially, PepGen reported a net loss of $69.1 million for 2022, an increase from $27.3 million in 2021. R&D expenses rose to $54.1 million, reflecting heightened clinical activities. The company has $181.8 million in cash, funding operations into early 2025. Overall, PepGen aims to develop transformative therapies for severe neuromuscular diseases.
PepGen Inc. (Nasdaq: PEPG) has presented promising clinical and nonclinical data for its Enhanced Oligonucleotide Delivery (EDO) platform at the MDA Conference in Dallas. The data highlights PGN-EDO51's ability to achieve a 34.9% exon skipping in non-human primates after four monthly doses, significantly higher than the 2.5% observed after a single dose. PepGen plans to initiate the CONNECT1-EDO51 Phase 2 study in DMD patients in the first half of 2023, with results expected in 2024. Additionally, the company aims to start the FREEDOM-DM1 Phase 1 study for myotonic dystrophy type 1 (DM1) patients in 2023, targeting safety and efficacy.
PepGen Inc. (Nasdaq: PEPG), a biotechnology company focused on oligonucleotide therapies, announced that its President and CEO, James McArthur, Ph.D., will present at Stifel’s CNS Days Conference on March 28, 2023, at 1:30 PM EST. The event aims to showcase PepGen's innovative approach to treating severe neuromuscular and neurological diseases through its Enhanced Delivery Oligonucleotide (EDO) platform, which leverages cell-penetrating peptides. A live webcast of the presentation will be available, with an archive for one year on PepGen's Investor Relations website.
PepGen Inc. (Nasdaq: PEPG) is set to report its fourth quarter and full year 2022 financial results on March 23, 2023. The clinical-stage biotechnology company focuses on advancing oligonucleotide therapies to treat severe neuromuscular and neurological diseases. PepGen's management will also host a conference call and audio webcast at 4:30 PM ET to discuss these results. The company employs an Enhanced Delivery Oligonucleotide (EDO) platform, leveraging cell-penetrating peptides to enhance therapeutic uptake and effectiveness. A replay of the event will be archived for one year.
PepGen Inc. (Nasdaq: PEPG) announced its participation in the Muscular Dystrophy Association (MDA) Annual Clinical and Scientific Conference from March 19-22, 2023, in Dallas, Texas. The company plans to present data on PGN EDO51 for Duchenne Muscular Dystrophy and PGN-EDODM1 for Myotonic Dystrophy Type 1, with presentations scheduled for March 22. Notably, PepGen will release a press statement after its presentations and provide access to the poster and data presentations on its Investor Relations website. The company's Enhanced Delivery Oligonucleotide platform aims to advance treatments for severe neuromuscular and neurological diseases.